Cullinan Therapeutics, Inc. (CGEM)
8.89
-0.18
(-1.98%)
USD |
NASDAQ |
Nov 20, 16:00
8.91
+0.02
(+0.22%)
After-Hours: 20:00
Cullinan Therapeutics Research and Development Expense (TTM) : 169.67M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 169.67M |
| June 30, 2026 | 171.47M |
| March 31, 2026 | 188.07M |
| December 31, 2025 | 187.40M |
| September 30, 2025 | 184.95M |
| June 30, 2025 | 178.49M |
| March 31, 2025 | 153.72M |
| December 31, 2024 | 142.90M |
| September 30, 2024 | 137.26M |
| June 30, 2024 | 135.57M |
| March 31, 2024 | 126.71M |
| December 31, 2023 | 148.16M |
| September 30, 2023 | 134.63M |
| Date | Value |
|---|---|
| June 30, 2023 | 120.49M |
| March 31, 2023 | 119.51M |
| December 31, 2022 | 91.95M |
| September 30, 2022 | 91.50M |
| June 30, 2022 | 84.50M |
| March 31, 2022 | 69.87M |
| December 31, 2021 | 57.75M |
| September 30, 2021 | 53.50M |
| June 30, 2021 | 50.74M |
| March 31, 2021 | 51.45M |
| December 31, 2020 | 43.21M |
| September 30, 2020 | 30.38M |
| June 30, 2020 | 25.75M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Climb Bio, Inc. | 43.60M |
| Oncolytics Biotech, Inc. | 13.18M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 647.26M |
| Anixa Biosciences, Inc. | 4.828M |